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Introduction Although PSA (prostate specific antigen) based screening for prostate cancer (PCa) is con-
troversial, an increasing number of men are undergoing Transrectal Ultrasound Guided prostate biopsy 
(TRUSPB) through primary care-based PSA testing and referral to hospitals. The aim of our study was to in-
vestigate presenting risk profiles of PCa over the last decade in a cohort of men in Ireland and to examine 
any change in the same over this time period.
Material and methods The hospital patient administration system was analysed for patients who under-
went TRUSPB from January 2005 to December 2015. Clinically significant PCa was defined as Gleason 
score of 7 or above.
Results Complete data was available on 2391 TRUSPB patients: number of biopsies increased by 53%, 
median age decreased by 0.9%, median PSA decreased by 6% (p = 0.001, ANOVA) and abnormal DRE 
increased by 9% (p = 0.001, chi square). Overall positive biopsy was 44% and significant cancer rate was 
21%. There was a significant change in trend of detection (p = 0.02) with average annual increase in signifi-
cant cancer of 3%. The median age of the significant cancer cohort reduced by 1% and the PSA at diagno-
sis reduced by 9%. In younger men (<50 years), the rate of significant cancer detection increased by 18%.
Conclusions Significant PCa detection increased across all age groups but recently, a younger patient  
profile was diagnosed with high-grade disease. This paves the way for future research on early-onset  
PCa. Younger patients with significant disease would result in increasing number of patients being eligible  
for radical treatment with implications on health resource planning and provision.
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INTRODUCTION
PSA (prostate specific antigen) based screening for 
prostate cancer (PCa) is controversial, but increasing. 
An increasing number of men are undergoing 
Transrectal Ultrasound Guided prostate biopsy 
(TRUSPB) through primary care-based prostate 
specific antigen (PSA) testing and referral to hos-
pitals. The incidence of prostate cancer is heavily 
influenced by the widespread use of PSA testing. 
The 2016 EAU guidelines suggest adopting a special-
ised risk-adapted strategy for early detection of pros-
tate cancer (Pca) in well-informed men with good per-
formance status and life expectancy of 10–15 years. 
The guidelines recommend offering PSA screening 
in men with an elevated risk of PCa along with ap-
propriate counseling on risks and benefits [1].
Currently, patients who have a high PSA or/and 
abnormal Digital Rectal Examination (DRE) are 
advised to undergo prostate biopsy. As of now, tran-
srectal ultrasound guided prostate biopsy (TRUS-
PB) is the most commonly used modality for tissue 
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diagnosis of PCa. This method was introduced in the 
mid 1980s and since then it has also seen significant 
changes in its execution [2]. Current recommenda-
tions are a 10–12 core TRUSPB in indicated patients.
According to the National Cancer Registry Ireland [3], 
there were 3,400 cases of PCa diagnosed between 
2011 and 2013, making up one-third of all male 
cancers detected in this period. Of the 28,432 pa-
tients diagnosed with PCa since 1994, 37% died by 
the end of 2013. PCa incidence is among the highest 
in Europe and incidence rates in Ireland are up to 
1.5 times higher than in the United Kingdom (UK) 
and Europe as of 2012 [4]. The etiology of PCa 
is still not clearly understood; genetic predisposition 
and environmental factors both seem to contribute. 
Age, ethnic background and family history are the 
most prominent risk factors. In recent years, inter-
est has arisen in the changing presenting risk profile 
of prostate cancer. The overall rate of new PCa diag-
nosis in the United States is dropping by an average 
of 5.1% per year while death rates have also been 
decreasing by 3.5% each year between 2004–2013 
[5]. Contrary to this, the age-standardised incidence 
of PCa in Ireland has been steadily rising at a rate 
of 1% per year in the last decade [4]. PCa incidence 
in the UK has increased by 155% since the 1970s and 
the age-standardised incidence in Europe has more 
than doubled [6].
There is limited published data on the changing dis-
ease risk profile at diagnosis. The aim of our study 
was to investigate presenting risk profiles of PCa over 
the last decade in a cohort of men in Ireland and to ex-
amine any change in the same over this time period.
MATERIAL AND METHODS
This was retrospective cohort study on patients who 
underwent TRUSPB in our hospital between Janu-
ary 2005 and December 2015. Ethical approval was 
obtained from the local ethics committee. The hos-
pital patient administration system was utilised 
for collection of data.
Patients with unknown histopathology result and 
patients who underwent trans-perineal biopsy of 
prostate were excluded. All biopsies were performed 
by four consultants over the ten-year period. TRUS 
biopsies were performed using a standard ultrasound 
and biopsy probe with prophylactic antimicrobial 
cover as per the current guidelines (oral Ciprofloxa-
cin 500 mg the morning and evening of biopsy and 
Gentamicin 240 mg IV at the time of biopsy).
Details were obtained on patient demographics, digi-
tal rectal examination (DRE) findings, PSA, biopsy 
cores and histology report. Clinically significant Pca 
was defined as Gleason score of 7 or above. Primary 
outcome measures were trends in patient risk pro-
file, cancer detection rates and Gleason grade. Our 
secondary outcome measures included demographic 
trends in the significant cancer sub-group and can-
cer detection rates in younger men (<50 years).
All data was analysed with SPSS version 24.0 and 
excel. Trends were expressed as average annual 
percent changes over the decade. P value of less 
than 0.05 was considered statistically significant. 
ANOVA, Student's t test and Chi-square tests were 
used where appropriate.
RESULTS
A total of 2391 TRUSPB biopsies were performed 
over the ten-year period. There was a 53% rise 
in TRUSPB performed in the center over the decade.
Age (Figure 1): The median age of the cohort was 
63 years. The median age of the patients undergoing 
TRUS biopsies decreased over the ten-year period by 
0.9% from 65 years to 63 years (p = 0.001, ANOVA). 
PSA (Figure 2): The median PSA of the cohort was 
Figure 1. Trends in age of men undergoing Transrectal Ultra-
sound Guided prostate biopsy over the last decade.
Figure 2. Trends in prostate specific antigen (PSA) at diagnosis 
in men undergoing prostate biopsy over the last decade.
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8.2. The median pre-biopsy PSA reduced by 6% over 
the decade (p = 0.001, ANOVA) from 10 (2005–2010) 
to 6.9 (2011–2015).
Biopsy cores: The median number of cores per bi-
opsy increased over time as expected by 15% per year 
from 4 (2005–2007), 8 (2008–2010) to 12 (2011–2015) 
(p = 0.001, ANOVA).
DRE (Figure 3): Overall 35% of patients undergoing 
TRUS biopsy had a suspicious/abnormal DRE. Pro-
portion of abnormal DRE increased over the decade 
by 9% (p = 0.001, chi square).
Cancer detection (Figure 4)
Subgroup analysis: significant cancer cohort
We performed a further subgroup analysis of the 
patients with a diagnosis of significant cancer 
(n = 494). We found the median age of the signifi-
cant cancer cohort was 65 years, which reduced 
by 1% per year over the period. The median age 
of this cohort in 2015 was 63 years, which was sig-
nificantly lower than that in 2005 of 71 years. The 
median PSA was 10.6 ng/ml in this cohort and 
it steadily declined by 7% per year over ten years, 
the initial median PSA in 2005 was 27 ng/ml which 
reduced significantly to 8.3 ng/ml by 2015. The ab-
normal DRE rate was 41.3%, which also increased 
by 48% over the ten-year period.
Subgroup analysis: younger men <50 years of age 
(Figure 5)
We analysed men of age equal to or less than 50 years 
who underwent TRUSPB in the institute (n = 61) 
and found a linear increase in the rate of significant 
cancer detection rate by 18%/year over the last de-
cade. The overall negative biopsy rates in this cohort 
was 65% (n–39), with a 25% (n = 15) overall signifi-
cant cancer detection rate.
DISCUSSION
Our study shows that the rate of TRUSPB being per-
formed in this single centre in Ireland rose dramati-
cally over the last decade. This study also showed 
that an increasing number of younger men are pre-
senting with lower PSA. This is likely a reflection 
of increased PSA testing.
Screening for PCa is currently the most controver-
sial topic in urological literature. The median age 
of PCa detection has reduced in the last 30 years, 
which could be attributed to PSA use. Annual 
screening with PSA increases lifetime risk of PCa 
diagnosis from 8% to 20% [1]. A population based 
study of PSA screening from Australia published 
in 2013, showed increasing incidence of PSA testing 
in men <55 years of age leading to modestly high-
er incidence of PCa in Australia [7]. Merits of PSA 
Figure 4. Trends in cancer detection in men undergoing pros-
tate biopsy in the last decade.
Figure 3. Trends in abnormal Digital Rectal Examination (DRE)  
rates prior to prostate biopsy.
Figure 5. Trends in significant cancer detection in men  
<50 years undergoing prostate biopsy over the last decade.
ural history of the disease and possible behavioral 
and environmental exposures leading to more ag-
gressive disease. We looked at PCa detection rates 
in the patients undergoing TRUSPB in the last de-
cade in this centre and found that although overall 
positive biopsy rates dropped over time, the signifi-
cant cancer detection rate increased by 3% per year 
over the last ten years.
This could in part be attributed to the changing 
format of TRUSPB in the last decade with increas-
ing number of core biopsies through the study pe-
riod. The median number of cores taken during the 
TRUSPB in this center rose from 4 to 12 in the last 
decade, in line with changing recommendations. 
The original six-core biopsy introduced by Hodge 
had a false negative rate of 22–30%. The cancer 
detection rate seems to increase with increasing 
number of cores: two consecutive sextant biopsies 
have a 75% cancer detection rate, two consecutive 
10-core biopsies have a 90% cancer detection rate 
[15]. The current EAU recommendation is to per-
form a 10–12 core TRUSPB.
We analysed demographic trends in patients with 
a diagnosis of significant PCa in the last decade and 
found increasingly younger men with lower PSA were 
being diagnosed with significant PCa. Further analy-
sis of younger men <50 years of age showed a steady 
rise in rate of significant cancer detection. There 
has been a rise in incidence of PCa in younger men 
in recent times by almost 5.7 fold with the median 
age at diagnosis shifting from 72 years in 1986 to 67 
years in 2009 [16]. In Ireland as well, the age group 
below 55 years shows the highest relative increase 
in PCa incidence [4]. Early onset PCa in men below 
the age of 55 years could be a distinct phenotype from 
an etiological and clinical perspective, with a possible 
strong genetic component. Though younger men are 
more likely to have low-grade disease, among men 
with high Gleason grade or locally advanced can-
cer at diagnosis, younger men are reported to have 
a particularly poor prognosis [16, 17]. Younger men 
with high-grade disease are at a much higher risk 
of death from PCa regardless of the type of therapy 
they undergo [17]. The declining age of the patient 
population being diagnosed with significant PCa 
also has serious implications on healthcare resource 
planning and allocation. These men have a longer 
life expectancy and hence are candidates for radi-
cal treatment. Studies have also showed that men 
younger than 65 years diagnosed with PCa often 
opt for curative treatment compared to their older 
counterparts and also place increased importance 
on functional outcomes of the treatment such as 
sexual function and urinary continence, the former 
being of increased consequence [16].
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screening are controversial and most guidelines 
recommend no PSA screening in men <40 years 
of age. The Surveillance, Epidemiology, and End 
Results (SEER) program has also showed that PSA 
screening in younger men has led to almost an ad-
ditional million men being over diagnosed and over 
treated for PCa, with no overall survival benefits [8]. 
The US Preventive Services Task Force (USPSTF) 
recommended against PSA screening in all men 
in 2012, since then the overall rates of PSA screening 
in the US have declined as has the incidence of early 
stage PCa [9]. PSA screening is not offered routinely 
in Ireland and other European countries. However, 
the National Cancer Registry in Ireland (NCRI) re-
ports an almost 9% rise in rates of PSA testing in Ire-
land based on laboratory data from 2008–2010 [10]. 
This increased rate of opportunistic PSA screening 
and consequent TRUSPB could be attributed to in-
creasing awareness and concern among the patient 
population secondary to the media, internet and 
possible increased screening in other family mem-
bers due to rising awareness of risk of familial PCa. 
Interestingly, in this study there was also an increase 
in the rate of abnormal DRE in patients undergoing 
TRUSPB, hence opportunistic PSA screening may 
not be the sole indication for rising rates of TRUSPB 
in this cohort.
With higher rates of opportunistic PSA screen-
ing, there has reportedly been a significant stage 
shift in PCa from locally, advanced metastatic PCa 
to early stage, lower volume PCa [11]. The NCRI 
reports a continued increase in T1 and T1c stag-
es of PCa in the last decade but leveling off of the 
T2 cancer cases in line with the overall incidence 
[4]. However, a recent report from the US showed 
a significant increase in the incidence of metastat-
ic PCa since 2007, the largest increase was seen 
in men aged 55–69 years [12]. They showed reduc-
tion in incidence of low-risk PCa, rise in interme-
diate and high risk PCa from 2004 to 2008 and 
a steady state in these trends there after. A 2013 
UK study by Greenberg and colleagues [13] found 
that there was a significant upward migration in 
intermediate and high-grade histological diagno-
sis of prostate cancer over the previous decade. Li 
and colleagues [14] in their study on trends in PCa 
also showed a significant increase in rate of poor-
ly differentiated PCa (Gleason 7 or more) in their 
study population from 2004–2007, with a simulta-
neous decrease in the well-differentiated and mod-
erately differentiated cancer groups. They labeled 
this partly because of the introduction of higher 
tertiary Gleason patterns and reporting different 
Gleason grades in multiple needle biopsies. Even 
so, we cannot completely rule out the changing nat-
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cant PCa detection increased across all age groups 
in the last decade but a younger patient profile was 
diagnosed with high-grade disease in recent times. 
This paves the way for future research on early-
onset PCa and studies looking at possible genetic 
or environmental factors contributing to this trend. 
Younger patients with significant disease would re-
sult in increasing number of patients being eligible 
for radical treatment with implications on health re-
source planning and provision.
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CONCLUSIONS
This trends study on patients undergoing TRUSPB 
in the last decade in a single center revealed an in-
creasing rate of biopsies inline with the incidence 
trend of PCa in Ireland. Younger men with lower 
PSA are increasingly undergoing biopsies reflecting 
the escalation in opportunistic PSA testing. Signifi-
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